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Heterozygous coding mutations in the INS gene that encodes pre-
proinsulinwere recently shown to be an important cause of perma-
nentneonataldiabetes. Thesedominantly actingmutationsprevent
normal foldingof proinsulin,which leads to beta-cell death through
endoplasmic reticulum stress and apoptosis. We now report 10 dif-
ferent recessive INSmutations in 15 probandswith neonatal diabe-
tes. Functional studies showed that recessive mutations resulted in
diabetes because of decreased insulin biosynthesis through distinct
mechanisms, including gene deletion, lack of the translation initia-
tionsignal, andalteredmRNAstabilitybecauseof thedisruptionofa
polyadenylation signal. A subset of recessive mutations caused
abnormal INS transcription, including the deletion of the C1 and
E1 cis regulatory elements, or three different single base-pair sub-
stitutions in a CC dinucleotide sequence located between E1 andA1
elements. In keeping with an earlier and more severe beta-cell
defect, patients with recessive INS mutations had a lower birth
weight (−3.2 SD score vs.−2.0 SD score) andwere diagnosed earlier
(median 1weekvs. 10weeks) compared to thosewithdominant INS
mutations. Mutations in the insulin gene can therefore result in
neonatal diabetes as a result of two contrasting pathogenic mech-
anisms. Moreover, the recessively inherited mutations provide a
genetic demonstration of the essential role of multiple sequence
elements that regulate the biosynthesis of insulin in man.
gene regulation | genetic testing | gene expression regulation | RNA
instability | promoter regions
Neonatal diabetes is diagnosed within the first 6 months of life(1, 2) and there are twomain clinical subtypes: the persistent,
permanent neonatal diabetes (PNDM) and the remitting and
frequently relapsing, transient neonatal diabetes (TNDM).
Recently there have been considerable advances in the under-
standing of the genetics of neonatal diabetes (3). Most patients
with PNDM have activating mutations in KCNJ11 or ABCC8, the
genes encoding the potassium ATP-sensitive (KATP) channel
subunits Kir6.2 (4) and SUR1 (5–7), or heterozygous mutations in
the preproinsulin (INS) gene (8–12). In contrast, abnormalities in
chromosome 6q24 are the most common cause of TNDM (13),
followed by mutations in the KCNJ11 and ABCC8 genes (14).
Despite these advances, the etiology of neonatal diabetes is still
not known in at least 30% of patients with PNDM, suggesting
other genetic causes are still to be found (9).
Insulin is secreted from islet beta cells of the pancreas. Insuffi-
cient secretion of insulin results in hyperglycemia and diabetes,
whereas excessive secretion results in hypoglycemia. Insulin bio-
synthesis and secretion are therefore tightly regulated to maintain
blood glucose levels within a narrow physiological range. Extensive
studies have dissected an array of cis sequence elements in the INS
promoter region and their cognate DNA binding factors, which
together ensure the cellular specificity and rate of INS transcription
(15–22). In addition, insulin biosynthesis is strongly dependent on
posttranscriptional regulatory mechanisms, including the modu-
lation of translation and stability (23–25). The latter is largely
mediated through sequences located in the untranslated regions of
INS transcripts (26–28).
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Heterozygous missense mutations in the coding region of the
INS gene have recently been described as a cause of neonatal
diabetes (8–12). Most of the reported mutations are predicted to
disrupt the folding of the proinsulin molecule. The resulting
misfolded protein accumulates in the endoplasmic reticulum
(ER), resulting in ER stress and beta-cell apoptosis (29, 30). An
alternative potential genetic mechanism would be reduced
insulin secretion because of a disruption of the INS coding
sequence, as seen in the double Ins1 and Ins2 knockout mouse
(31), or of the sequences that regulate insulin biosynthesis.
However, as yet this has not been demonstrated in humans.
We now report recessively actingmutations within the INS gene
in a series of patients with neonatal diabetes. In contrast to the
previously described dominant mutations, these mutations reduce
insulin synthesis and thus represent a unique pathogenic mecha-
nism for human diabetes. These mutations also provide genetic
evidence for the essential role of distinct nucleotide sequences in
the regulation of the human preproinsulin gene.
Results
Recessive INS Mutations Cause Neonatal Diabetes. We sequenced
117 unrelated probands with diabetes diagnosed before 6 months
(13 offspring of consanguineous parents) in whom the known
common genetic causes had been excluded. We identified 10 dif-
ferent INS recessive mutations in 15 unrelated families (Figs. 1
and 2). Four homozygous mutations affected the coding region:
c.184C>T (p.Q62X), c.3G>T (p.0?), c.3G>A(p.0?), and a large
deletion that removes a segment of the promoter, exon 1 and
coding exon 2 of INS (c.-370-?_186+?del). Five homozygous
mutations were found in regulatory regions: c.-331C > A (2 fam-
ilies), c.-331C > G (5 families), c.-218A > C, and a 24-base pair
deletion (c.-366_-343del) are located in the promoter region,
whereas c.*59A > G is within the 3′ untranslated region. One
proband was a compound heterozygote for two regulatory region
mutations, c.-331C > G and c.-332C > G.
The mutations were inherited in a recessive manner either
homozygous or compound heterozygous, with heterozygous
carrier parents being unaffected with neonatal diabetes (Fig. 2).
Pathogenicity of mutations was suggested by conservation across
species and absence of variants in controls (Table S1).
Recessive INS Mutations Uncover Essential Regulatory Sequences in
Humans. Further support for the pathogenicity of mutations came
from known function of mutated residues and functional studies
(Figs. 3 and Figs. 4; see also SI Results). Multiple mutation
mechanisms were involved in the recessive INS mutations, which
are described briefly below.
Truncated proteins. The nonsense mutation (p.Q62X) is predicted
to give rise to a mutant protein that is truncated within the C-
peptide region and will lack the insulin-A chain.
Promoter mutations. The (c.-366_-343del) 24-base pair deletion
abolishes the INS promoter evolutionary conserved C1 and E1
elements, whereMAFA andNEUROD1 bind, respectively (16, 20,
32) (Fig. 3A). The c.-218A>Cmutationdisrupts theCRE3 site that
interactswithmultipleDNAbinding proteins in vitro (22) (Fig. 3A).
All of these elements have been previously shown to be critically
important for the INS promoter activity in transient transfection
studies (15, 18, 33–35). The c.-331(C >G, C >A) and c.-332C >G
mutations were located between the E1 and A1 elements (Fig. 3A).
This sequence is conserved among a subset of mammalian species
(Fig. 3A) and mutagenesis of multiple bases neighboring this
dinucleotide impairs INS promoter activity (36). We constructed
insulin promoter fragments carrying the pointmutations c.-331(C>
G,C>A)and c.-332C>G.The pointmutations induced up to 90%
reduction in transcriptional activity, while a control mutation, c.-
339G > A, did not alter the transcriptional activity in pancreatic
beta-cell lines (Fig. 3B). Thus, the CC dinucleotide that is mutated
in eight unrelated probands with neonatal diabetes forms part of an
essential positive cis regulatory sequence of the INS promoter.
Mutated or absent translational start site. The two point mutations
(c.3G > A and c.3G > T) at the first methionine residue (p.Met1)
abolish the native translation initiation site for the preproinsulin
protein. Quantification of total INS mRNA levels by real-time
PCR revealed no differences in mRNA abundance for c.3G > A
or c.3G > T mutations compared with the wild type. The insulin
content of HeLa cells transfected with these mutations was
reduced by 86% and 79% for c.3G > A and c.3G > T, respec-
tively, compared to cells transfected with the wild-type sequence
(Fig. 4A and SI Results). The multiexon deletion (exons 1 and 2)
removes over half the coding region including the translational
start site and is expected to be a null mutation.
Altered mRNA stability through a mutation in the 3′ untranslated region.
The c.*59A >Gmutation is located in the polyadenylation signal
of the 3′ untranslated region and potentially impairs mRNA sta-
bility. In a heterozygous lymphoblastoid cell line generated from
the proband’smother, themutantmRNA transcript was present at
a very low level compared to the wild-type allele. This is consistent
with reduced mRNA stability (Fig. 4B and SI Results).
Clinical Phenotype of Patients with Recessive INS Mutations. The
clinical characteristics of patients with recessive INS mutations
are shown in Table 1 (Table S1 and S2). In keeping with the
known actions of insulin before and after birth, the phenotype
was limited to markedly reduced fetal growth and diabetes.
The diabetes phenotype within the families is shown in Fig. 2.
Nineteen patients had neonatal diabetes (15 probands and 4 family
members); 14 had PNDM and were treated with insulin from
diagnosis, and 5 patients had TNDM, having gone into remission at
a median age of 12 weeks [interquartile range (IQR) 11, 22]. Birth
weight was markedly reduced in all patients with neonatal diabetes
resulting from recessive mutations [median birth weight 1,680 g
(1,420; 2,050), which is−3.2 SD score (−4.1,−2.6)]. In keeping with
more severe insulin deficiency, patients with PNDM had a more
severe intrauterine growth retardation [median SD score for birth
weight −3.9 (−4.4, −2.8) vs. −1.8 (−3.4, −0.9) in TNDM, P= 0.03]
anddiabeteswas diagnosed earlier [2 days (1, 9.5) vs. 24 days (5, 62),
P = 0.04] (Table S3). All patients with mutations that altered the
coding region or mRNA stability had PNDM. The noncoding pro-
moter mutations were associated with both PNDM and TNDM. A
summary of the remaining 98 patients with neonatal diabetes of
unknown origin is given in Table S4.
Fig. 1. A schematic of the INS gene showing the 10 muta-
tions identified in 15 families. Positions of point mutations
are indicated below the exons, while deletions are shown
above the gene. The blue shaded regions are noncoding, the
red text indicates a deletion, the blue text are noncoding
mutations, and the green are coding mutations. The precise
breakpoints of the multiexonic deletion are not known; the
solid line represents the minimal deleted region. Mutation
nomenclature is based on the coding sequence where
nucleotide 1 represents translational start site.
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Differences in the Clinical Phenotype with Recessive and Dominant
INS Mutations. To identify whether the different mutation
mechanisms in the same gene resulted in phenotypic differences,
we compared the clinical characteristics of patients with neonatal
diabetes as a result of recessive INS mutations with patients with
the previously identified dominant mutations in INS (Table 1).
Patients with neonatal diabetes resulting from recessive INS
mutations had a markedly different phenotype, with lower birth
weight [median SD score −3.2 (IQR −4.1, −2.6) vs. −2.0 (−2.5,
−1.0), P < 0.001] and an earlier age of diagnosis [median age in
weeks 1 (0, 3) vs. 10 (5, 22), P < 0.001]. TNDM is only seen in
patients with recessive mutations (26 vs. 0%, P= 0.001). Overall,
recessive INS mutations accounted for 3.7% PNDM (n = 300)
and 2.2% TNDM (n = 134) in a consecutive series of patients
with isolated neonatal diabetes referred to the two laboratories
for genetic testing.
Discussion
We have shown that recessively acting mutations in the pre-
proinsulin gene (INS) are a cause of neonatal diabetes. They act by
reducing synthesis of the preproinsulin peptide because of a
truncated protein, abnormal transcription, reduced mRNA sta-
bility, or disrupted translation. These mutations usually cause
PNDM but may manifest as TNDM or diabetes outside the neo-
natal period. In keeping with the recessive inheritance, many
probands (60%) were the offspring of consanguineous parents.
The clinical manifestations of recessive INS mutations reflect
the consequences of insulin deficiency in humans during pre- and
postnatal life. The birth weight was markedly reduced [median
SD score −3.2 (−4.1, −2.6)], consistent with the major role of
insulin in fetal growth. The early onset of neonatal diabetes
(median 1 week) reflects severe insulin deficiency postnatally. In
contrast to many other subtypes of neonatal diabetes, there are
no extrapancreatic features.
Differences in the underlying pathophysiology explain why
patients with recessive INS mutations are diagnosed earlier and
have a lower birth weight than patients with heterozygous INS
mutations (8–12). The disrupted insulin synthesis seen with
recessive mutations occurs as soon as the fetal beta cell starts to
secrete insulin. In contrast, insulin secretion is required before
beta-cell dysfunction develops in patients with heterozygous
mutations, which result inmisfolding of the preproinsulin peptide,
accumulation of the misfolded protein in the ER, and hence the
destruction of the beta cell through ER stress. These two distinct
diseasemechanisms are supported by phenotypic studies inmouse
models, where reduced insulin secretion at birth or progressiveER
Fig. 2. Partial pedigrees of the 15 families with reces-
sive INS mutations. (Del, deletion; n, Normal allele; M,
mutation). Solid black-filled shapes represent patients
with permanent neonatal diabetes, gray filled shapes
represent patients with transient neonatal diabetes,
and shapes filled with diagonal lines represent those
patients diagnosed with diabetes after 6 months of
age. Age at diagnosis and remission (where applicable)
are shown below the symbols.
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stress and cell death have been described in mice carrying analo-
gous recessive or dominant mutations, respectively (30, 31, 37).
The majority of the patients with neonatal diabetes have
PNDM, but 26% (5 of 19) have TNDM. TNDM is only found in
patients with noncoding mutations and they have a higher birth
weight and are diagnosed later. This finding is consistent with
TNDM resulting from a less severe insulin deficiency, and is
comparable to the situation with mutations in the Kir6.2 subunit
of the KATP mutations (38), where TNDM mutations have less
severe functional consequences. The mechanism of remission in
recessive INS mutation carriers is not understood but is likely to
reflect a variation in demand or the ability of the beta cell to
meet this demand, as a similar timing of remission is seen in
some patients with less severe mutations, resulting in channelo-
pathies (14, 38) and pancreatic developmental defects (39, 40).
The mutations identified in this study illustrate multiple mecha-
nisms by which insulin biosynthesis can be disrupted. These include
absent or altered translation because of coding-sequence deletions
or mutations, reduced transcription because of mutations of the
promoter, or abnormal mRNA stability. Our functional studies
established that the 3′ UTR mutation that abolishes the poly-
adenylation signal results in severe RNA instability and that the
initiation codon mutations result in reduced transcription of the
preproinsulin gene. The promotermutations are highly informative
because they provide human genetic evidence that discrete INS cis
regulatory elements are essential. Numerous studies have demon-
strated that multiple cis elements are required for the activity of
episomal INS reporter constructs in cultured cells (15, 17–19, 21,
22). However, it is not known if each of those cis elements is truly
necessary in vivo, because such studies can only partially predict
their function in the integrated chromatin environment of bona fide
differentiated cells. Studies in other selected genes have addressed
this by targeted deletion of transcriptional regulatory elements in
mice (41). Our findings now reveal that the C1/E1, CC, and CRE3
elements are essential for INS gene transcription in humans. The
discovery of three separate mutations that target the CC dinucleo-
tide sequence is particularly significant. This element forms part of a
canonical CCACC binding-site motif for Kruppel-like zinc-finger
proteins. Two recent studies have shown that artificial mutations of
this CCACC element lead to decreased INS promoter activity (36,
42). Although previous studies failed to identify protein complexes
interacting with this region in beta-cell nuclear extracts (17, 36), a
recent study showed that in vitro translated GLIS3, a zinc-finger
transcription factor that is mutated in patients with neonatal dia-
betes and congenital hypothyroidism (43), exhibits sequence-spe-
cific binding to this region (42). Multiple DNA binding factors may
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Fig. 3. Functional evidence for the pathogenicity of recessive promoter INSmutations. (A) Schematic of the genomic sequence of the INS promoter structure
with major cis regulatory elements, and the sequence context of mutated elements in several mammalian species that do not exhibit major divergence in these
regions. Mutated bases are highlighted in red. The numbering of promoter landmarks is relative to the transcription start site (genomic numbering, where g.1 is
equivalent to c.-238) consistentwith the convention used in previous studies. Mutations are described according to HumanGenomeVariation Society guidelines
(http://www.hgvs.org/mutnomen/) (cDNA numbering according to the translational start site where c.1 is equivalent to g.238), and distance to the conventional
INS transcriptional start site is shown in parenthesis. (B) Evidence for loss-of-function of the c.-331(C > G, C > A) and c.-332C > G mutations. Firefly luciferase
expression is compared in constructs containing the wild-type (WT) INS promoter sequence (INS WT), or c.-331 C > G, c.-331 C > A, c.-332 C > G, c.-339G > A
mutations, after transfection inMIN6 β-cells. Data shown aremeans (+/−SE) from three independent constructs for eachmutation (n = 3 replicates). c.-339G>A is
a control mutation that does not impair INS transcription. Results are corrected for transfection efficiency using a vector that constitutively expresses Renilla
luciferase, and are expressed relative to the INSWT results. The asterisks denote P< 0.0001 in ANOVA for the difference between INSWTandmutant constructs.
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bind to CCACC elements in vitro, and thus future studies are war-
ranted to determine if additional factors act through this element in
vivo in beta cells. Our findings, therefore, demonstrate that the
natural CC elementmutations that cause diabetes disrupt INS gene
activity and establish the importance of this cis regulatory element.
In conclusion, we have shown that homozygous INS mutations
are a unique cause of neonatal diabetes. The mutations result in
reduced synthesis of the insulin polypeptide through a variety of
mechanisms and may yield further insights into the regulation of
insulin biosynthesis.
Materials and Methods
Cohort Characteristics. We studied an international cohort of 117 unrelated
patients (67 males) with diabetes diagnosed before 6 months (median age 4
weeks)andwithoutaknowngenetic etiology,whichwere referred totheExeter
(n = 105) or Bilbao laboratories (n = 12). Thirteen patients were offspring of
consanguineousparents (second-degree relatives or closer). In the 100probands
with PNDM, we excluded mutations in KCNJ11, ABCC8, GCK, and previously
described heterozygous coding mutations in INS (9). In the 17 patients with
TNDM,we excluded 6q24 anomalies, KCNJ11, andABBC8mutations. Remission
was defined as the disappearance of clinical symptoms with normalization of
blood glucose or HbA1c for a period longer than 15 days after withdrawal of
insulin therapy. Babies born before 33 weeks of gestation were excluded to
avoid hyperglycemia of prematurity. Studies were approved by Cruces Hospital
committee and North and East Devon Research Ethics Committee. Informed
consent was obtained from all patients or their parents and the studies were
conducted in line with the Declaration of Helsinki. Clinical data were obtained
from the patients’ clinical records. We calculated standard deviation scores for
birth weight (44).
Molecular Genetic Analysis. Genomic DNA was extracted from peripheral
leukocytes using standard procedures. Regulatory elements up to 450 bp
upstream of the transcriptional start site and exons 1 to 3 of the INS gene (Fig.
1) were amplified by the PCR in three amplicons (primers and conditions
available on request). Unidirectional sequencing was carried out on an
ABI3730 (Applied Biosystems) and analyzed using Mutation Surveyor v3.20.
Sequences were compared with the published sequence (Ensembl sequence
ENSG00000129965) and published polymorphisms. The genomic reference
sequence nucleotide 1 is the transcriptional start site (g.1A or c.-238A),
whereas the translational start site is located at g.238 (c.1). Mutation
nomenclature is shown in compliance with the Human Genome Variation
Society, where nucleotide 1 represents the A of the translational start-site
codon ATG (c.1). Suspected mutations were tested for conservation across
species and cosegregation within families. Putative gene deletions were
investigated using multiplex ligation-dependent probe amplification assay
oligonucleotide probes specific for the three exons of INS (see SI Materials
and Methods).
Functional Studies. Investigating the effect of INS promoter mutations on
transcriptional activity. To determine the functional impact of the c.-331(C >
G, C > A) and c.-332C > G mutations we performed site-directed mutagenesis
of an INS promoter firefly luciferase reporter construct (pSOUAPRL-251hINS-
Luc), and compared the activity of control and mutated promoters in MIN6
β-cells, using a Renilla luciferase promoter (pGL4.75) to correct for differences
in transfection efficiency (see SI Materials and Methods).
Investigating the effect of the translation initiation mutations (c.3G > T and c.3G >
A). To determine the effect of these mutations on insulin production, we
transfected HeLa cells, which do not express insulin, with wild-type or mutant
INS and analyzed intracellular insulin content using radio-immunoassay (SI
Materials and Methods).
Investigating the effect of the c.*59A > G mutation on mRNA stability. We
determined the effect of the c.*59A > G mutation on insulin mRNA stability
using real time PCR to measure the relative levels of the INS mRNA
transcripts in a heterozygous lymphoblastoid cell line derived from the
proband’s mother. We used a heterozygous SNP, rs3842753, to identify the
mutation bearing allele (SI Materials and Methods).
Statistical Analysis. Clinical numeric data are given as median (IRQ range).
Functional data are given as mean (SE). The clinical features of patients were
compared using Kruskal-Wallis, χ2 (Fisher’s exact) tests or Mann-Whitney U in
the statistical package SPSS version 13. Student’s t-test or analysis of variance
was used for expression studies.
Fig. 4. Functional evidence for the pathogenicity of recessive INS mutations
affecting translation and mRNA stability (A) Homozygous mutations in the
translation initiation codon of the INS gene result in reduced insulin content of
transfected HeLa cells. The insulin content of HeLa cells was measured by RIA
after transfection with wild-type insulin (INS WT) or either of two INS mutant
constructs, as shown. Both nucleotide changes were identified in patients with
permanent neonatal diabetes. Nonspecific values obtained with HeLa cells
transfectedwith empty vectorwere subtracted from all samples and those data
are presented as mean +/− SE (n = 3 replicates). (B) Allele-specific quantitative
real-timePCRof c.*59A>Gandnormal transcripts. Thegraph shows the relative
abundance of the wild-type and mutant RNA transcripts in mutant and normal
cell lines. The rs3842753A allele tags the c.*59A (wild type, shown ingreen); the
c.*59G (mutant) was tagged by rs3842753 C allele (blue). The graph shows the
level of transcripts in the control sample heterozygous only for rs3842753 and in
thematernal sample (familyDM1165),which isheterozygous forbothrs3842753
and c.*59A/G. The level of themutant transcript is reduced to less than 3 × 10−4
percent comparedwith thenormal transcript in theheterozygousc.*59A>Gcell
line. Experimental error as calculated from the standard deviation of the repli-
cate experiments is indicated. The standard deviation for the quantification of
the c.*59G allele in the maternal sample is 3 × 10−6, and thus the experimental
error is not visible in the figure.
Table 1. Comparison of clinical characteristics in patients with
isolated neonatal diabetes with recessive and dominant INS
mutations
Characteristic INS recessive INS dominant P-value
n 19 46 NA
Sex, % male 63.2 47.8 0.3
Birth weight, g 1,680 (1,410; 2,050) 2,530 (2,350; 2,900) <0.001
Gestational age,
wk
37.5 (36, 40) 40 (38.5, 40) 0.008
Birth weight,
SD score
−3.2 (−4.1, −2.6) −2.0 (−2.5, −1.0) <0.001
Age at diagnosis,
wk
1 (0, 3) 10 (5, 22) <0.001
Remission, % 26 0 0.001
Age at remission,
wk
12 (11, 22) NA NA
Age at relapse, yr 1 (only 1 case) NA NA
Current age, yr 5 (2, 14) 11 (4, 23) 0.2
Data are median (interquartile range). NA, not applicable.
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SI Results
Large Deletion Detected by Multiplex Ligation-Dependent Probe
Amplification. A large deletion encompassing the promoter
region, the noncoding exon 1 and coding exon 2 of INS (c.-370-?_
186+?del) was identified in a large consanguineous Lebanese
family (ISPAD 182). The deletion was identified following failure
of PCR amplification of INS exons 1 and 2. Themultiplex ligation-
dependent probe amplification (MLPA) assay showed that the
parents had a 50% reduction in dosage for exons 1 and 2 but two
copies of exon 3. Testing the proband and affected cousin showed
that INSexon 1 and2MLPAprobes didnot bind to the targetDNA
(suggestive of a homozygous deletion).
Effect of the Translation Initiation Codon Mutations on Insulin
Content. The homozygous mutations c.3G > T and c.3G > A
were identified in two unrelated probands with permanent dia-
betes diagnosed on the first day of life. Both are nonsynonymous
changes affecting the first methionine residue (p.Met1) and
abolishing the translation initiation site for the preproinsulin
protein. A second methionine residue is located at codon 5 (p.
Met5), but the surrounding sequence does not conform to the
Kozak consensus for translation because a thymine base is present
at position−3 to the ATG codon rather than the required adenine
(1).We would therefore predict that translation from the mutated
initiator codon would be compromised but without experimental
evidencewe could not rule out a possible effect onmRNAstability.
To investigate the possibility that these p.0? mutations (c.3G >
T and c.3G > A) could affect mRNA stability, we quantified the
amount of INS mRNA in HeLa cells expressing wild-type or
mutation bearing plasmids by real-time PCR. There were no
differences in the amount of INS mRNA expressed in cells
transfected with either mutation compared with cells transfected
with wild-type plasmids [INS wild-type: INS c.3G > T and INS
wild-type: INS: c.3G > A ratios were 1:0.99 (SD = 0.19) and
1:0.95 (SD = 0.15) respectively; P = 0.87].
To investigate the possibility of low levels of translation from p.
Met5, we used an in vitro radio-immunoassay to measured insulin
content incellsexpressingthemutationscomparedtocellsexpressing
wild type (WT) INS.The cells expressing INS (WT) contained 56 pg
of insulin per million cells, while the insulin content was reduced by
at least 79% in the cells expressing INS c.3G>T and c.3G>A (11.9
and 7.6pg of insulin per million cells respectively) (Fig. 4A). These
data show that p.Met5 is unlikely to reinitiate translation of pre-
proinsulin in the presence of the c.3G > T or c.3G > A mutations.
Effect of the c.*59A > G Mutation on RNA Stability. To investigate
the effect of the c.*59A > G mutation on RNA stability we used
real-time PCR to quantify the level of INS mRNA transcripts in
a heterozygous lymphoblastoid cell line generated from the
proband’s mother (DM1165). We were unable to discriminate
between the transcripts directly via the c.*59A/G alleles, as the
mutation was located at the far 3′ end of the transcript. Instead,
we used a SNP (rs3842753) to tag the mutation, with the mu-
tation (c.*59G) on the same haplotype as the C allele of the
SNP. The mutation-bearing transcript was not detectable in the
heterozygous mother (Fig. 4B) and in the homozygous state we
predict that the affected child will not express the INS gene.
SI Materials and Methods
Gene-Dosage Analysis Using MLPA. We designed MLPA assay oli-
gonucleotide probes (sequences available on request) to measure
the number of copies of INS exons 1 to 3 using probes forHNF1A
and HNF4A as controls (method previously described by ref. 2).
Methodology for the Investigation of the Effect of Promoter
Mutations on Insulin Gene Promoter Activity. A plasmid containing
nucleotides c.-489 to c.-228 of the human insulin gene promoter
(pSOUAPRL-251hINS-Luc) linked to the firefly luciferase gene
(Roland Stein, Vanderbilt University) was used to perform site-
directed mutagenesis with the QuikChange kit (Stratagene). Three
independent clones were created for each base substitution. The
plasmidswere verifiedbydirect sequencing, andassayed in transient
transfection assays in triplicate on three separate occasions, as
described (3). MIN6 β cells were trypsinized 24 h before trans-
fection, plated into 24-well plates (1 × 105 cells per well) and
maintained in DMEM supplemented with 15% FBS, 2 mM Glu-
tamine, and 50 nM 2-Mercaptoethanol. Cells were transfected with
promoter-luciferase constructs (500 ng) using Metafectene PRO
(Biontex), following manufacturers instructions. pGL4.75[hRluc/
CMV] (10 ng) was included in the transfections to normalize for
transfection efficiency. Twenty-four hours posttransfection, Firefly
and Renilla luciferase activity was assayed using Dual-Luciferase
Reporter Assay System (Promega), and the ratios were expressed
relative to the wild-type insulin promoter values.
Methodology for Investigating the Effect of the Translation Initiation
Codon Mutations (c.3G > T and c.3G > A). cDNA encoding wild-type
INS and both mutant forms of INS-p.0?,c.3G > T and c.3G > A,
were cloned into pcDNA 3.1/myc-His A, which uses a CMV and
T7 promoter to drive high level expression of the recombinant
protein. Correct insertion was verified by sequencing of the
plasmids. Next, 4 × 106 HeLa cells were cotransfected with 8-μg
pcDNA 3.1 and 8-μg pMAX GFP using Nucleofector technology
(Amaxa/Lonza) according to the manufacturer’s instructions.
GFP expression was examined by fluorescence microscopy to
monitor transfection efficiency. Control cells were transfected
with empty pcDNA3.1 vector.
Noninsulin expressing HeLa cells were cultured in DMEM
Glutamax medium (Gibco Life Technologies) supplemented with
5% FBS, 100 units/mL penicillin, and 100 μg/mL streptomycin at
37 °C in a fully humidified atmosphere of 5% CO2.
To rule out an effect of these mutations on mRNA stability,
we quantified the amount of INS mRNA relative to the Beta-2-
microglobulin (B2M) gene in transfected cells. Total RNA was
extracted from ≈1 × 106 HeLa cells using the Perfect RNA Mini
RNAkit (Eppendorf). Next, 4.5 μgmRNAwas treatedwith 2 units
of RNase-free DNase (TURBO DNase kit, Ambion) to remove
Genomic DNA by following the manufacturer’s instructions.
cDNA was synthesized from mRNA using the Thermoscript RT-
PCR system (Life Technologies) with an incubation temperature
of 50 °C and a random hexamer primer. PCR products were de-
tected by the use of a probe situated across the boundary of exons 2
and 3 to ensure amplification from cDNA rather than genomic
DNA (forward primer; CGGGAGGCAGAGGACCT, reverse
primer; AGGCTGCCTGCACCAG, probe; 6FAM- AC-
CTGCCCCACCTGC-MGB). Reactions contained 5-μLTaqMan
Fast Universal PCR Master Mix, no AmpErase, 0.9 μM each pri-
mer and 0.25 μMprobe in a total volumeof 10 μLon theABI prism
7900HT platform (Applied Biosystems). Amplification conditions
were a single cycle of 95 °C for 20 s followed by 60 cycles of 95 °C for
1 s, and 60 °C for 20 s. The results given are an average of quan-
tifications from three replicate amplifications.
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Expression levels of the mutant and wild-type transcripts were
measured by comparing the number of cycles at which the INS
and B2M PCR products cross a specific threshold. The relative
abundance is defined by the difference in number of cycles to
achieve the same quantity of product and calculated using the
equation 2−ΔΔCt, where ΔΔCt is the difference between the
crossing points (ΔCttest) in a test sample normalized to a refer-
ence sample (ΔCtref) (Applied Biosystems). Differences in the
mRNA abundance for wild-type and mutant transcripts were
examined for statistical significance by Kruskal–Wallis test.
The insulin content of transfectedHeLa cells was determined 24
h posttransfection by radio-immunoassay. Briefly, cells were lysed
in 200 μL of acidified ethanol (0.8 MHCl:98% ethanol mixed in a
ratio of 1:3) for 2 h at −20 °C and samples then neutralized by
addition of NaOH. In triplicate, 50 μL of each experimental
sample or crystalline recombinant human insulin standard was
mixed with 50 μL of 125I insulin (Linco; diluted to yield ≈2,000
cpm/50 μL) and 50 μL Guinea Pig anti-bovine insulin antibody
(ICN) diluted 1:20,000 in insulin assay buffer (IAB; 150mMNaCl,
30mMNa2HPO4, 10mMKH2PO4, 10mMEDTA, 5mg/mLBSA,
pH7.4). Tubes were incubated at 4 °C overnight before addition of
50 μLof donkey anti-Guinea Pig coated cellulose beads (IDSLtd.)
(diluted 1:1 with IAB). After incubation for 1 h, 2-mL dH2O was
added and tubes centrifuged for 5 min at 1,000 × g. The super-
natant was aspirated under vacuum and the radioactivity retained
in each pellet measured on a WALLAC gamma counter. The in-
sulin content of each sample was then calculated by reference to a
standard curve constructed with recombinant human insulin.
Methodology for Investigating the Effect of the c.*59A > G Mutation
on mRNA Stability. Cell lines were established from peripheral
blood lymphocytes derived from the proband’s heterozygous
mother (DM1165) and an unaffected control by EBV trans-
formation. Cell lines were maintained in 1× RPMI-1640 (Gibco
Life Technologies), supplemented with 10% FCS (Gibco Life
Technologies).
Total RNA was extracted from ≈1 × 106 EBV-transformed
lymphoblastoid cells using the Perfect RNA Mini RNA kit
(Eppendorf). Next, 4.5 μg mRNA was treated with 2 units of
RNase-free DNase (TURBO DNase kit, Ambion) 30 min at
37 °C followed by 85 °C for 5 min for nuclease inactivation.
CDNA (cDNA) was synthesized from mRNA using the Ther-
moscript RT-PCR system (Life Technologies) with an incubation
temperature of 50 °C and a random hexamer primer.
EctopicmRNA transcripts were amplified from lymphoblastoid
cells using a single tube TaqMan approach. It was not possible to
design probes for the c.*59A >Gmutation because of its location
at the extreme 3′ end of the transcript. Instead we used a hetero-
zygous single nucleotide polymorphism (rs3842753) located 37
nucleotides upstream of the poly-A tail to differentiate the mu-
tation-bearing and normal transcripts. Probe and primer se-
quences were designed to this variant and validated by standard
curve analysis [Forward – 5′ ggagaactactgcaactagac 3′, Reverse – 5′
catctctctcggtgcaggag 3′, Probe (WT) – VIC-cagccccAcacccg-
MGB, Probe (MT) – 6-FAM-agccccCcacccg-MGB].
Two microliters cDNA from the proband’s mother (hetero-
zygous for c.*59A > G and rs3842753) was used for real-time
PCR quantification and cDNA from a normal cell line (hetero-
zygous for rs3842753 only). PCR products were detected by the
use of mutation-specific probes which were identical except for
the site of the mutation. Reactions contained 5-μL TaqMan Fast
Universal PCR Master Mix, no AmpErase, 0.36 μM each primer,
and 0.08 μM each probe in a total volume of 10 μL on the ABI
prism 7900HT platform (Applied Biosystems). Amplification
conditions were a single cycle of 95 °C for 20 s, followed by 60
cycles of 95 °C for 1 s, and 60 °C for 20 s. The results given are an
average of quantifications from three triplicate amplifications
derived from two separate RNA extractions.
To validate the real-time assay, we conducted standard curve
analysis, which indicated that the assay was accurate and quan-
titative over seven serial 1:2 dilutions. The efficiency of ampli-
fication as assessed by the gradient of the standard curves for
mutant and wild-type probes were −3.1 and −3.0, respectively.
The correlation between crossing point and input template (r2)
was 0.95 and 0.92 for the mutant and wild-type probes, re-
spectively. The A- and C-allele transcripts of rs3842753 are
present in approximately equal amounts in the normal hetero-
zygous cell line, indicating that the presence of this SNP does not
adversely affect the stability of either allele.
Expression levels of the mutant and wild-type transcripts were
measured using the allele-specific assays by comparing the number
of cycles at which the two different PCR products cross a specific
threshold. The relative abundance is defined by the difference in
number of cycles to achieve the same quantity of product and
calculatedusing the equation 2−ΔΔCt, whereΔΔCt is the difference
between the crossing points [(ΔCttest) in a test sample normalized
to the difference between mutant and normal crossing points in a
50:50 mixture (ΔCt50%) (Applied Biosystems (4)].
1. Kozak M (1989) Circumstances and mechanisms of inhibition of translation by
secondary structure in eucaryotic mRNAs. Mol Cell Biol 9:5134–5142.
2. Ellard S, et al. (2007) Partial and whole gene deletion mutations of the GCK and HNF1A
genes in maturity-onset diabetes of the young. Diabetologia 50:2313–2317.
3. Hansen SK, et al. (2002) Genetic evidence that HNF-1alpha-dependent transcriptional
control of HNF-4alpha is essential for human pancreatic beta cell function. J Clin Invest
110:827–833.
4. Applied Biosystems (2001) Relative quantitation of gene expression.User Bulletin 2:11–15.
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Table S1. Assessment of pathogenicity of noncoding mutations giving data on the conservation of the nucleotides and the number of
control chromosome sequences tested
Variant n Conservation
Control chromosomes sequenced
for variant
Experimental evidence for
loss of function
Chimp Rhesus Tree shrew Mouse Rat
c.-332C > G 1 Yes C Yes C Yes C Yes C Yes C 496 Yes
c.-331C > G
c.-331C > A
7 Yes C Yes C No T Yes C Yes C 496 Yes
c.-218A > C 1 Yes A Yes A Yes A Yes A Yes A 496 ND
c.*59A > G 1 Yes A Yes A Yes A Yes A Yes A 496 Yes
The variants were not detected in any of the control chromosomes. ND, not done.
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Table S3. Comparison of clinical characteristics in patients with permanent or transient
neonatal diabetes caused by recessive INS mutation
Characteristic Transient Permanent P-value
n 5 14 NA
Type of mutation (% regulatory) 100 64 0.3
Sex (% male) 80 57 0.6
Birth weight (g) 2,540 (1,860; 2,650) 1,500 (1,300; 1,800) 0.007
Gestational age (wk) 38 (37.5, 40) 37 (36, 40) 0.3
Birth weight (SD score) −1.8 (−3.4, −0.9) −3.9 (−4.4, −2.8) 0.03
Age at diagnosis (days) 24 (5, 62) 2 (1, 9.5) 0.04
Glucose at diagnosis (mmol/L) 27 (18, 31) 22 (15, 31) 0.7
Bicarbonate at diagnosis (mmol/L) 9 (7, 12) 23 (20, 24) 0.06
Remission (%) 100 0 NA
Age at remission (wk) 12 (11, 22) NA NA
Age at relapse (yr) 1 (1 case) NA NA
Current age (yr) 2 (1.5, 3) 10 (4, 18) 0.02
Current HbA1c (%) 5.5 (4.8, 6.1) 8.3 (6.7, 8.9) 0.04
Data are median (interquartile range). NA, not applicable.
Table S4. Clinical characteristics in patients with isolated neonatal diabetes without mutations
in any of the reported genes
Characteristic Transient Permanent P-value
n 13 85 NA
Sex (% male) 64 56 0.8
Birth weight (g) 2250 (2077, 2933) 2725 (1900, 3213) 0.5
Gestational age (wk) 40 (37, 40) 39 (37, 40) 0.8
Birth weight (SD score) −1.6 (-2.9, -0.8) −1.1 (-2.5, -0.3) 0.4
Age at diagnosis (wk) 3 (1, 8) 5 (1, 22) 0.4
Remission (%) 100 0 NA
Age at remission (wk) 17 (6, 48) NA NA
Relapse (%) 38.5 0 NA
Age at relapse (yr) 4 (2, 5.5) NA NA
Data are median (interquartile range). NA, not applicable.
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